SynthesisWorld journal of surgical oncology2026
Transarterial radioembolization versus transarterial chemoembolization for tumor control and survival outcomes in early to intermediate stage hepatocellular carcinoma: systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransarterial radioembolization (TARE) is increasingly used as an alternate and potentially superior treatment option to Transarterial chemoembolization (TACE) for early- to intermediate-stage unresectable hepatocellular carcinoma (HCC). However, randomized controlled trials (RCTs) comparing the two modalities have reported mixed findings, and the comparative efficacy and safety remain uncertain.
methodsA comprehensive literature search was conducted across five databases until August 2025, following PRISMA guidelines. Only RCTs comparing Yttrium-90 TARE (Y90-TARE) with TACE in adults with early- to intermediate-stage unresectable HCC were included. The primary outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Secondary outcomes were adverse events, quality of life, and downstaging for liver transplantation. The quality of the evidence was assessed using the GRADE framework.
resultsFour RCTs comprising 169 patients (TARE = 87, TACE = 82) were included. No significant differences were observed in PFS (HR: 0.72, 95% CI: 0.43–1.20; P = 0.21), OS (HR: 0.82, 95% CI: 0.49–1.35; P = 0.43), ORR (OR: 1.32, 95% CI: 0.60–2.93; P = 0.49), and downstaging to liver transplantation (OR, 2.19; 95% CI, 0.85–5.66; P = 0.11). However, TARE was associated with significantly fewer treatment-related adverse events (OR, 0.38; 95% CI, 0.19–0.75; P = 0.005). The quality-of-life outcomes were comparable.
conclusionPatients with early to intermediate stage HCC, treated with TARE and TACE, had similar survival outcomes. TARE appears to have a better safety profile with fewer treatment-related adverse events. The limitations of the current data suggest that prospective comparative studies including larger number of patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.